Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Pfizer’s ambitious gene therapy for Duchenne muscular dystrophy fails to meet efficacy targets, prompting strategic retreat and industry-wide …
Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
Already a subscriber? Log in